> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDC Recommends COVID-19 Vaccines for Nearly 20 Million Children Under 5 After FDA Authorizes Moderna and Pfizer
- URL: https://www.theamericanquorum.com/taq-historical-2022-06-18-healthcare/
- Published: 2022-06-19T03:59:00.000Z
- Updated: 2022-06-19T03:59:00.000Z
- Description: CDC endorsed COVID-19 vaccination for children as young as 6 months, completing U.S. eligibility after FDA authorized Moderna and Pfizer pediatric regimens.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-08-31 13:56

The Centers for Disease Control and Prevention on Saturday recommended COVID-19 vaccination for children as young as 6 months, opening eligibility to nearly 20 million additional U.S. children and making vaccines available across essentially the full population beyond early infancy. The decision followed the Food and Drug Administration’s authorization Friday of separate Moderna and Pfizer-BioNTech regimens for the youngest age groups.

CDC Director Rochelle Walensky endorsed a unanimous recommendation from the Advisory Committee on Immunization Practices, saying in a [June 18 statement](https://archive.cdc.gov/www%5Fcdc%5Fgov/media/releases/2022/s0618-children-vaccine.html?ref=theamericanquorum.com) that children 6 months through 5 years should receive a COVID-19 vaccine. The recommendation allows families to begin choosing between two products that use the same mRNA platform but differ materially in dose, number of injections and timing.

## Two vaccines, two different pediatric regimens

The FDA’s [authorization announcement](https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-for-children-down-to-6-months-of-age-301570340.html?ref=theamericanquorum.com) expanded Moderna’s vaccine to children 6 months through 17 years and Pfizer-BioNTech’s vaccine to children 6 months through 4 years. For the youngest children, Moderna is administered as two 25-microgram doses four weeks apart. Pfizer-BioNTech uses a three-dose series at 3 micrograms per dose, with the first two doses three weeks apart and the third given at least eight weeks after the second.

The committee’s [evidence-to-recommendations framework](https://www.cdc.gov/acip/evidence-to-recommendations/covid-19-moderna-pfizer-children-vaccine-etr.html?ref=theamericanquorum.com) recorded 12-0 votes for both products. ACIP concluded that the desirable consequences of vaccination clearly outweigh the undesirable consequences for most children in these age groups. The panel reviewed immunogenicity, observed vaccine effectiveness during the Omicron period, safety, the burden of disease in young children and parents’ ability to access vaccination.

The vaccines are not interchangeable in schedule. A family choosing Moderna can complete the initial series in about a month. Pfizer’s three-dose schedule extends over at least 11 weeks. That difference matters operationally because immunity develops over time, and because the country is entering summer with highly transmissible Omicron subvariants still circulating.

## Trials relied heavily on immune response during Omicron

Pfizer and BioNTech said in their [authorization release](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use?ref=theamericanquorum.com) that the three-dose 3-microgram series produced a strong immune response in children 6 months through 4 years and had a favorable safety profile similar to placebo in its Phase 2/3 trial. The companies selected the lower pediatric dose to balance immune response and tolerability.

Moderna said in its [June 17 announcement](https://www.newswire.com/news/moderna-receives-fda-authorization-for-emergency-use-of-its-covid-19-vaccine?ref=theamericanquorum.com) that its 25-microgram two-dose series was authorized for children 6 months through 5 years, while higher pediatric doses were authorized for older children and adolescents. The company’s trial evaluated immune responses and symptomatic infection during a period when Omicron was dominant, a substantially different viral environment from the original adult vaccine trials conducted before widespread variants.

Because relatively few severe pediatric outcomes occurred inside the randomized trials, regulators relied on an approach known as immunobridging: comparing neutralizing-antibody responses in young children with responses in older participants in whom vaccine efficacy had already been established. The FDA also reviewed available descriptive estimates of protection against symptomatic infection and safety data across thousands of trial participants.

## The decision closes the last major age gap

The authorization ends a long period in which parents of children under 5 had no vaccine option even as older children, adolescents and adults became eligible in stages. The White House had already outlined a [distribution plan](https://www.presidency.ucsb.edu/documents/fact-sheet-biden-administration-announces-operational-plan-for-covid-19-vaccinations-for?ref=theamericanquorum.com) on June 9, saying the federal government had made 10 million initial doses available for states, pharmacies, pediatric practices, community health centers and other providers if regulators authorized the shots.

The youngest children generally face lower rates of severe COVID-19 than older adults, but their risk is not zero. Hospitalizations increased during the winter Omicron wave, and children with no underlying medical conditions accounted for a substantial share of pediatric admissions. Regulators also weighed the broader effects of infection, including missed childcare and work, transmission within households and the possibility of post-infectious complications.

CDC’s recommendation applies even to children who have already had COVID-19\. The agency says prior infection can provide some protection but that vaccination adds a more predictable immune response. Parents are being advised to discuss timing with pediatricians, particularly if a child was recently infected or has a history of severe allergic reactions.

## Safety monitoring will continue after rollout

The regulatory process does not end with authorization. CDC and FDA will monitor reports through systems including the Vaccine Adverse Event Reporting System and CDC’s v-safe program. The agencies have paid particular attention to myocarditis and pericarditis after mRNA vaccination in adolescents and young adults, especially males, but the pattern has been much less prominent in younger age groups and the doses authorized for small children are substantially lower.

The two products also create a real-world test of how families weigh speed, familiarity and dosing schedules. Some parents may prefer Moderna’s two-dose course; others may choose Pfizer because older children or adults in the household have already received that brand. Federal guidance does not express a preference between the authorized options for the youngest age group.

For the administration, the decision is a milestone in a vaccination program that has progressed by age since late 2020\. For pediatricians, it begins a more complicated phase centered less on mass vaccination sites and more on conversations with parents in ordinary clinical settings. For families, it adds a preventive option that has been unavailable throughout the first two years of the pandemic.

The central fact as of this weekend is that the eligibility gap has closed. FDA has authorized both pediatric mRNA approaches, ACIP has recommended them, and CDC has endorsed vaccination beginning at 6 months of age. Distribution is underway, with the first appointments expected to begin in the coming days.